Bethanechol chloride is a prescription medication that mimics the action of the nervous system’s own chemical messenger, acetylcholine, to stimulate smooth muscle contraction, primarily in the bladder and the gastrointestinal tract. It has been used for decades to help people who cannot empty their bladder adequately after surgery, childbirth, or nerve injury. Despite its long history, the clinical evidence behind bethanechol is more complicated than its continued use might suggest, with some studies showing clear benefit and others finding little measurable improvement in voiding.
How Bethanechol Makes Muscles Contract
Bethanechol belongs to a class of drugs called cholinergic agonists. It binds to muscarinic receptors on smooth muscle cells, triggering the same type of contraction that the body’s own acetylcholine would produce. The key advantage over acetylcholine itself is durability: acetylcholine breaks down almost instantly in the body, while bethanechol resists the enzymes that would normally chew it up. That gives it a much longer window of action after a dose.
In laboratory studies on bladder tissue, bethanechol produces dose-dependent contractions that are actually more potent than acetylcholine, generating higher peak contractile force at lower concentrations. These contractions depend on muscarinic receptor activation and require both intracellular and extracellular calcium to work properly. When calcium channels were blocked or calcium was removed from the surrounding fluid, the contractile response dropped dramatically.1Research in Veterinary Science. Effects of bethanechol on canine urinary bladder smooth muscle function This mechanism is why bethanechol acts selectively on smooth muscle rather than skeletal muscle or the heart.
Because it activates muscarinic receptors broadly, bethanechol does not limit its effects to a single organ. It can increase motility in the esophagus, stomach, and intestines, boost salivary gland secretion, and lower pressure in the anal sphincter. That broad profile explains both its range of clinical uses and its side effects.
Urinary Retention After Surgery and Childbirth
The most common reason bethanechol gets prescribed is urinary retention, the inability to fully empty the bladder. This happens frequently after surgical procedures, spinal anesthesia, or childbirth, when the bladder’s detrusor muscle temporarily loses its ability to contract with enough force. The drug is also used in certain neurological conditions where nerve damage impairs bladder signaling.
In the postpartum setting, bethanechol has shown promise for reducing the need for re-catheterization. Postpartum urinary retention is common, and early treatment with bethanechol appears to be most effective in the initial phase of the condition, before the bladder has become overdistended.2Journal of Population Therapeutics and Clinical Pharmacology. Oral Bethanechol in Postpartum Urinary Retention The idea is straightforward: give the drug while the bladder muscle still has tone and simply needs a chemical push to start contracting again.
For neurogenic bladder dysfunction caused by spinal cord injury or other nerve damage, the picture is more specific. Bethanechol works best in select situations where the bladder’s inability to empty comes from weak or unsustained detrusor contractions rather than a structural blockage. Conditions where it has been recommended include early-phase reflex bladder dysfunction with incomplete emptying, the recovery stage of spinal shock once the urethral sphincter is back under voluntary control, and sensory paralytic bladder with decompensation.3PubMed. Bethanechol chloride in neurogenic bladder dysfunction The common thread is that the plumbing has to be open; if something is physically blocking urine flow, pushing the bladder to contract harder is dangerous, not helpful.
After radical hysterectomy for cervical cancer, which can damage the nerves controlling the bladder, early treatment with bethanechol improved several measures of bladder function. Patients showed lower post-void residual volumes, higher flow rates, and more efficient detrusor contractions compared to placebo.4PubMed. The effects of bethanechol and cisapride on urodynamic parameters in patients undergoing radical hysterectomy for cervical cancer
Mixed Evidence and the Case Against Routine Use
For all its decades of clinical use, the evidence supporting bethanechol is not as strong as you might expect. Several studies have found that while the drug changes measurable bladder parameters on urodynamic testing, those changes do not always translate into meaningful improvements in how well people actually void.
One study in women with significant residual urine volumes found that bethanechol did alter cystometric readings, confirming it was pharmacologically active. But the measurements that matter most to patients, residual urine volume and urine flow rate, did not improve.5PubMed. The effects of bethanechol chloride on urodynamic parameters in normal women and in women with significant residual urine volumes The drug was doing something to the bladder, just not the right something for those patients.
A systematic review and meta-analysis looking at parasympathomimetic drugs (a class that includes bethanechol) for underactive bladder painted a nuanced picture. When pooling the available trials, the drugs did reduce the proportion of patients who experienced urinary retention, cutting the risk roughly in half compared to control treatments. There was also a meaningful reduction in residual urine volume during the first week after treatment. But by one month, that advantage disappeared. And the overall quality of the evidence was rated low.6PubMed Central. The effectiveness of parasympathomimetics for treating underactive bladder: A systematic review and meta-analysis So bethanechol seems to help in the short term, particularly in acute retention, but it is not a reliable long-term solution for a chronically sluggish bladder.
A review article on detrusor underactivity was even blunter, concluding that the available data showed no definite benefit from parasympathomimetic agents for that condition, and noting that one meta-analysis had found bethanechol ineffective for promoting bladder emptying overall.7PubMed Central. Detrusor underactivity: To tone or not to tone the bladder? This is the central tension with bethanechol: clinicians keep prescribing it because there are few alternatives, but the evidence base is thin and inconsistent.
Gastroesophageal Reflux and Lower Esophageal Sphincter Pressure
Beyond the bladder, bethanechol has a history of use for gastroesophageal reflux disease. The logic is that the same muscarinic receptor activation that contracts the bladder also tightens the lower esophageal sphincter, the ring of muscle that keeps stomach acid from washing back up into the esophagus. In people with reflux, that sphincter is often too weak.
A study comparing bethanechol to metoclopramide (another drug used for reflux) in men with low sphincter pressure found that a 25 mg oral dose of bethanechol significantly increased lower esophageal sphincter pressure compared to placebo.8Gastroenterology. Comparative Effects of Metoclopramide and Bethanechol on Lower Esophageal Sphincter Pressure in Reflux Patients In pediatric patients, bethanechol reduced both the frequency and duration of reflux episodes, an effect researchers attributed to the combination of higher sphincter pressure and increased esophageal peristalsis helping to clear acid more quickly.9PubMed. Use of bethanechol for the treatment of gastroesophageal reflux
In practice, bethanechol has largely been replaced for reflux by proton pump inhibitors and H2 blockers, which suppress acid production directly rather than trying to keep the sphincter closed. But the reflux application illustrates how the drug’s broad smooth-muscle effects can be redirected to different organs depending on the clinical need.
Counteracting Anticholinergic Drug Side Effects
One of bethanechol’s more practical uses has been managing the side effects of other medications, particularly tricyclic antidepressants. Tricyclics work partly by blocking acetylcholine receptors, which is great for depression but creates a cluster of uncomfortable side effects: dry mouth, constipation, difficulty urinating, and blurred vision. These side effects cause a significant number of patients to stop taking their antidepressants.
Bethanechol, being a cholinergic agonist, essentially fills in for the acetylcholine that the antidepressant is blocking. It has been used to relieve dry mouth, constipation, and bladder inhibition in patients on tricyclic therapy, potentially allowing people to stay on their antidepressant who might otherwise quit due to side effects.10PubMed. The use of bethanechol chloride with tricyclic antidepressants This is a somewhat elegant pharmacological workaround: rather than switching to a different antidepressant, you add a second drug that directly opposes the first drug’s unwanted effects while leaving its antidepressant action largely intact.
With the decline in tricyclic prescribing in favor of SSRIs and newer antidepressants, this particular use has become less common. But the same principle applies whenever anticholinergic side effects from any medication become problematic enough to warrant treatment.
Topical Bethanechol for Anal Fissures
A less well-known application of bethanechol involves applying it as a gel directly to the anal sphincter to treat chronic anal fissures. Fissures are small tears in the anal lining that fail to heal because the internal anal sphincter is in spasm, reducing blood flow to the area. The treatment goal is to relax that sphincter enough to let healing happen.
A study testing topical bethanechol gel found that a 0.1% concentration produced a dose-dependent reduction in anal sphincter pressure, with a maximum decrease of about 24%. The effect lasted three to five hours, and no systemic side effects were observed.11PubMed Central. Topical diltiazem and bethanechol decrease anal sphincter pressure without side effects This seems counterintuitive at first. Bethanechol contracts smooth muscle elsewhere in the body, so why would it relax the anal sphincter? The answer lies in the specific innervation of the internal anal sphincter, where cholinergic stimulation actually triggers relaxation through a different signaling pathway than in the bladder or esophagus. The topical route also avoids the systemic side effects that make oral bethanechol unpleasant for some patients.
Safety Profile and Who Should Not Take It
Bethanechol’s side effects follow predictably from its mechanism. By activating muscarinic receptors throughout the body, it can cause sweating, flushing, abdominal cramps, nausea, diarrhea, salivation, and a sensation of warmth. These effects tend to be dose-related and are more pronounced when the drug is taken on an empty stomach. Most are annoying rather than dangerous, and they resolve when the drug is stopped.
The more serious concern is using bethanechol when it should not be used at all. The drug is contraindicated in people with mechanical obstruction anywhere in the urinary tract or gastrointestinal tract. If the bladder outlet is blocked by an enlarged prostate or a stricture, forcing the bladder to contract harder could rupture the bladder wall. The same logic applies to the GI tract: if there is a bowel obstruction, increasing motility upstream of the blockage is a recipe for perforation. Other contraindications include situations where the integrity of the bladder or GI wall is already compromised, as well as hyperthyroidism and peptic ulcer disease, both of which can be worsened by cholinergic stimulation.
The meta-analysis on parasympathomimetics for underactive bladder found no significant difference in adverse events between the drug and comparison groups, suggesting that at standard doses, bethanechol is generally tolerable for most people.12PubMed Central. The effectiveness of parasympathomimetics for treating underactive bladder: A systematic review and meta-analysis But tolerability in a trial population does not mean safety in every patient, particularly when the contraindications are not properly screened for.
Risks in Older Adults
Bethanechol deserves particular caution in elderly patients. A national study of medications associated with injury in elderly Medicare and Medicaid enrollees found that bethanechol had the highest proportion of emergency department visits per fill among all genitourinary products, at roughly 7.8 per 1,000 fills.13PubMed. National study of medications associated with injury in elderly Medicare/Medicaid dual enrollees during 2003 To put that in context, the only drug in the entire study with a higher proportion of emergency visits was methadone.
This finding is striking because bethanechol was not, at the time of the study, included on the Beers list, the widely used catalog of potentially inappropriate medications for older adults. The reasons for these emergency visits likely relate to the gastrointestinal and cardiovascular effects of cholinergic stimulation in a population that is already vulnerable to falls, hypotension, and GI complications. Older adults are also more likely to have undiagnosed partial obstructions, particularly bladder outlet obstruction from prostatic enlargement, which makes bethanechol particularly dangerous. If you are caring for an elderly family member who has been prescribed bethanechol, it is worth asking the prescriber whether the benefits justify the risk in that specific patient.
Veterinary Use in Dogs and Cats
Bethanechol is not just a human medication. It is the most commonly used drug for bladder dysfunction in dogs and cats, prescribed when pets cannot empty their bladders due to nerve damage, post-surgical complications, or conditions like feline idiopathic cystitis.14PubMed Central. Rational Use of Bethanechol in Dogs and Cats with Bladder Dysfunction The pharmacology is essentially the same as in humans: the drug stimulates detrusor contraction through muscarinic receptor activation.
Interestingly, a telemetry study in beagle dogs that monitored bladder function continuously over 15 days of oral bethanechol treatment found no significant changes in bladder function at any time point, even though the drug was being administered at standard veterinary doses.15PubMed Central. Urodynamic investigation by telemetry in Beagle dogs: validation and effects of oral administration of current urological drugs: a pilot study This mirrors the frustrating pattern seen in some human studies: laboratory evidence shows bethanechol clearly contracts bladder muscle, but oral dosing in a living animal does not always produce the expected clinical improvement. The gap likely reflects the complexity of urination as a coordinated process involving not just the detrusor muscle but also sphincter relaxation, neural timing, and bladder sensation, none of which bethanechol addresses directly.
Despite this evidence gap, bethanechol remains in widespread veterinary use for the same reason it persists in human medicine: there are very few alternatives for pharmacologically stimulating a weak bladder, and some animals do seem to respond even if controlled studies struggle to capture that benefit consistently. Veterinarians typically combine bethanechol with other strategies like manual bladder expression, catheterization, and treatment of any underlying cause.
Why a Decades-Old Drug Remains Controversial
Bethanechol occupies an unusual position in pharmacology. Its mechanism is well understood, its ability to contract isolated bladder muscle in a lab is beyond dispute, and it has been in clinical use since the mid-twentieth century. Yet the clinical trial data remains surprisingly weak, the quality of evidence is generally rated low, and newer reviews keep questioning whether it actually helps patients void better in real-world conditions. Part of the problem is that most of the foundational studies are old, small, and poorly controlled by modern standards. Running large, rigorous trials on a cheap generic drug with no patent protection holds little commercial appeal, so the evidence base is unlikely to improve dramatically.
The other part of the problem is biological. Urination and gastrointestinal motility are complex coordinated events, not simple on-off muscle contractions. Bethanechol can make the bladder squeeze harder, but if the sphincter does not relax in sync, or if the neural signals coordinating the whole process are disrupted, a stronger squeeze alone will not solve the problem. That is probably why the drug works best in acute, reversible retention, where the coordination machinery is intact and just needs a temporary boost, and falls short in chronic conditions where the underlying wiring is permanently damaged.